Abstract: The invention relates to novel particulate drug-delivery systems based on a polymer support containing at least one linear, branched or cross-linked polymer in a fraction of over 50 percent by weight in relation to the total weight of the support. The system is characterized in that at least one signal substance for transport through a biological barrier and at least one active ingredient are stored, the support, signal substance and active ingredient having no covalent links and no active-ingredient specific and signal substance specific coordinative links between one another.

Abstract: The invention relates to novel particulate drug-delivery systems based on a polymer support containing at least one linear, branched or cross-linked polymer in a fraction of over 50 percent by weight in relation to the total weight of the support. The system is characterised in that at least one signal substance for transport through a biological barrier and at least one active ingredient are stored, the support, signal substance and active ingredient having no covalent links and no active-ingredient specific and signal substance specific coordinative links between one another.

Abstract: The invention relates to novel particulate drug-delivery systems based on a polymer support containing at least one linear, branched or cross-linked polymer in a fraction of over 50 percent by weight in relation to the total weight of the support. The system is characterized in that at least one signal substance for transport through a biological barrier and at least one active ingredient are stored, the support, signal substance and active ingredient having no covalent links and no active-ingredient specific and signal substance specific coordinative links between one another.

Abstract: The invention relates to novel particulate drug-delivery systems based on a polymer support containing at least one linear, branched or cross-linked polymer in a fraction of over 50 percent by weight in relation to the total weight of the support. The system is characterised in that at least one signal substance for transport through a biological barrier and at least one active ingredient are stored, the support, signal substance and active ingredient having no covalent links and no active-ingredient specific and signal substance specific coordinative links between one another.

Abstract: Polymer blends comprising:(A) 99.5-0.5 wt. % of a copolymer comprising:a1) 50-99 wt. % of C.sub.1 -C.sub.10 -alkyl- or C.sub.5 -C.sub.8 -cycloalkylethacrylates or mixtures thereof,a2) 0.5-20 wt. % of maleic acid anhydride or fumaric acid anhydride or maleimide, anda3) 0.5-40 wt. % of vinyl aromatics which may be unsubstituted or substituted on the aromatic ring with 1 or 2 alkyl groups of 1 to 4 carbon atoms; and(B) 0.5-99.5 wt. % of a copolymer comprising:b) 99.5-50 wt. % of styrene and/or .alpha.-methyl styreneb2) 0.5-50 wt. % of acrylonitrile and/or methacrylonitrile;provide thermoplastic transparent molding compositions.

Abstract: Polymer blends comprising:(A) 99.5-0.5 wt. % of a copolymer comprising:a1) 50-99 wt. % of C.sub.1 -C.sub.10 -alkyl- or C.sub.5 -C.sub.8 -cycloalkylmethacrylates or mixtures thereof,a2) 0.5-20 wt. % of maleic acid anhydride or fumaric acid anhydride or maleimide, anda3) 0.5-40 wt. % of vinyl aromatics which may be unsubstituted or substituted on the aromatic ring with 1 or 2 alkyl groups of 1 to 4 carbon atoms; and(B) 0.5-99.5 wt. % of a copolymer comprising:b1) 99.5-50 wt. % of styrene and/or .alpha.-methyl styreneb2) 0.5-50 wt. % of acrylonitrile and/or methacrylonitrile;provide thermoplastic transparent molding compositions.